الأحد 30 جماد أول 1438 هـ 26 فبراير 2017 - 02:12 مساء



أخبار عالمية
خبر
القراءة
British Council and EU Commission Ask ... 5541
Smaller firms may face pollution limits 4850
GREEN PARTY OF THE UNITED STATES 4684
Greens welcome EU ban on live export subsidies 4415
Green Party MEP for South-East England 4276
London's Green MEP Warns Long Hours May Cost Londons Workforce Its Health 4254
Cameron's organic overtures 'meaningless',says Green MEP 4167
Further privatisation of NHS not the answer 4111
Herculean effort needed to save Olympic sports 4102
The Tories are not for turning - Keith Taylor 4100
أخبار عالمية
خبر
التاريخ
بيان من حزب الخضر اللبناني 29/01/2012
The Asia Pacific Greens Network 03/10/2011
The African Greens Mourn the Death of Prof.Wangari Maathai 27/09/2011
GREEN PARTY OF THE UNITED STATES 15/09/2011
GREEN PARTY OF THE UNITED STATES 08/09/2011
GREEN PARTY OF THE UNITED STATES 27/08/2011
DEMOCRATIC GREEN PARTY OF RWANDA 13/07/2011
GREEN PARTY OF THE UNITED STATES 16/05/2011
GREEN PARTY OF THE UNITED STATES 05/05/2011
GREEN PARTY OF THE UNITED STATES 27/03/2011


أحلامنا المشتركة -> Greens Press -> Herceptin need careful evaluation of clinicaleffectiveness
عدد مرات القراءة 21082006-02-21

Green Party in England & Wales

 

Herceptin need careful evaluation of clinical effectiveness

With Herceptin, the drug claimed by its manufacture to reduce the risk of early stage breast cancer returning, hitting the headlines daily, the Green Party have urged caution to ensure that the media interest and pressure from Roche do not influence its approval. Herceptin is not licensed for use in early stage breast cancer and there are concerns about its side effects. Roche have applied for a licence and the National Institute for Clinical Excellence (NICE) have agreed to fast track the review of its effectiveness (1).

Stuart Jeffery, Green Party Health spokesperson said: "Herceptin may or may not be a wonder drug. With the news that Roche has applied for a licence for its use in early stage breast cancer, we urge NICE not to bow to media or commercial pressure in their review of clinical and cost effectiveness. If it is approved and is later found not to be clinically effective, it will only be Roche's profits that benefit.

"It would be a great tragedy if this drug turned out to be another Vioxx (2), however the chances of a mistake in the assessment happening will be far less if NICE are allowed to form an impartial opinion.

"Should this drug receive NICE approval, the government must also fund its use and not expect the beleaguered NHS to try find the £100 million each year (1) that it will cost - otherwise other services will be cut."






بعد كل هذا الفشل في اعداد تشريعات الانتخابات البرلمانية..هل توافق علي الغاء الانتخابات
نعم
لا
لا اهتم


 
 


جميع الحقوق محفوظة للمشرف العام